Skip to main content

Find Clinical Trials

Home
Conditions
Marginal Zone Lymphoma

Clinical trial condition

Marginal Zone Lymphoma

Explore clinical trials studying Marginal Zone Lymphoma. Study availability and eligibility vary by location and protocol.

114 public trials 41 recruiting studies

Refine in advanced search Browse all conditions

Marginal Zone Lymphoma trial results

Recruiting

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

NCT05296070

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: City of Hope National Medical Center Duarte, California, United States

University of Miami Miami, Florida, United States

Emory University Atlanta, Georgia, United States

Vanderbilt University Nashville, Tennessee, United States

View Trial Details

Recruiting

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

NCT05326308

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +30 more
Locations: Universitätsklinikum Salzburg, Klinik für Innere Medizin III Salzburg, Austria

Lübecker Onkologische Schwerpunktpraxis Lübeck, Schleswig-Holstein, Germany

View Trial Details

Recruiting

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

NCT06792825

Conditions: Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: Masonic Cancer Center Minneapolis, Minnesota, United States

View Trial Details

Recruiting

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

NCT06340737

Conditions: Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +38 more
Locations: Stanford University Palo Alto, California, United States

View Trial Details

Recruiting

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

NCT05281809

Conditions: B Acute Lymphoblastic Leukemia, B-cell Lymphoma, Burkitt Lymphoma, +36 more
Locations: AHN Cancer Institute - West Penn Hospital Pittsburgh, Pennsylvania, United States

View Trial Details

Recruiting

Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)

NCT06534463

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Shanghai Ruijin Hospital Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

NCT06566807

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University#Huai'an First People's Hospital# Huai'an, Jiangsu, China

View Trial Details

Recruiting

Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

NCT06478472

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Bing, Xu Xiamen, Fujian, China

View Trial Details

Recruiting

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

NCT06513234

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: China Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences Tianjin, China

View Trial Details

Recruiting

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

NCT06454968

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Peking Union Medical College Hospital Beijing, Beijing Municipality, China

View Trial Details